Azenta posted third‑quarter revenue of $161 million, a 12% year‑over‑year rise, while adjusted EBITDA grew to $18 million, reflecting improved operating performance. The earnings beat supports the ongoing turnaround, offering investors a clearer path to profitability and cash‑flow generation.
Key Highlights
- Q3 revenue reached $161 million, up 12% YoY with 9% organic growth.
- Adjusted EBITDA totaled $18 million, an 11.4% margin, down 60 bps from the prior year.
- $50 million of shares were repurchased, retiring 2.3 million shares under the $250 million buyback program.
Azenta (NASDAQ: AZTA) reported third‑quarter revenue of $161 million, a 12% increase from the prior year, while adjusted EBITDA rose to $18 million. The company posted a total diluted EPS of $0.05, outperforming the prior‑year loss of $1.05. The results underscore a strengthening of recurring‑revenue streams amid a challenging market backdrop.
Revenue Beats Expectations
Third‑quarter revenue from continuing operations reached $161 million, up 12% YoY, with organic growth of 9% after adjusting for foreign‑exchange effects and the UK Biocentre acquisition. Sample Management Solutions contributed $88 million, a 14% rise, while Multiomics delivered $73 million, a 10% increase. The revenue surge reflects higher demand for Sample Repository Solutions, consumables, instruments, and next‑generation sequencing.
Compared with peers, ALMR fell 0.5% and FTRE rose 1.4% on the day, highlighting Azenta’s relative outperformance. This revenue acceleration improves top‑line visibility, essential for investors monitoring the company’s turnaround trajectory.
Adjusted EBITDA and Margin Details
Adjusted EBITDA for the quarter stood at $18 million, translating to an 11.4% margin, though this represents a 60‑basis‑point decline from the prior year’s 12.1% margin. The margin contraction stemmed from lower sales volumes affecting fixed‑cost absorption and quality remediation costs in Automated Stores, partially offset by operating leverage and cost‑initiative benefits. Adjusted operating income was $4.7 million, while non‑GAAP diluted EPS from continuing operations was $0.16, marginally below last year’s $0.17.
The modest EBITDA growth signals that cost controls are taking effect, yet investors must watch for further margin pressure as the company scales.
Cash Position and Share Repurchase
Operating cash flow was only $1 million, and free cash flow turned negative $5 million after $7 million of capital expenditures. The board’s $250 million share repurchase program, initiated in December 2025, saw $50 million spent to retire 2.3 million shares, reinforcing shareholder returns. The sizable cash balance combined with a disciplined buyback illustrates financial flexibility, but the negative free cash flow underscores the need for continued revenue growth to sustain cash generation.
Outlook and Upcoming Call
Management guided full‑year revenue from continuing operations between $613 million and $618 million, tightening the prior range of $603 million to $621 million, and expects organic revenue to be flat to up 1% versus a prior outlook of down 2% to up 1%. Adjusted EBITDA is projected at $20 million‑$23 million, with free cash flow anticipated to improve 10%‑15% YoY.
Peers Moving on This News
- Alamar Biosciences Inc (ALMR) down 0.5%
- Fortrea Holdings Inc (FTRE) up 1.4%
- Maravai LifeSciences Holdings Inc (MRVI) up 0.9%
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...